Sexual maturation modifies the catecholaminergic control of gonadotrophin secretion and the effect of ovarian hormones on hypothalamic neurotransmitters in female rats.
alpha-Methyl-p-tyrosine (alpha-MT), a competitive inhibitor of tyrosine hydroxylase, was used to block the synthesis of hypothalamic catecholamines in immature female rats of 14, 16 and 30 days of age and in castrated adults. The administration of alpha-MT (300 mg/kg body weight, free base) induced a significant decay in the hypothalamic content of norepinephrine (NE) and dopamine (DA) within the first 120 min. A second dose (150 mg/kg body weight), given 2 h after the first injection, did not further modify the low catecholamine levels observed 120 min after the first alpha-MT administration. The administration of 300 mg/kg body weight of alpha-MT induced a significant increase in LH concentrations in rats aged 14 and 16 days. On the contrary, after an alpha-MT injection, a significant LH decrease was observed in 30-day-old and in adult castrated rats. alpha-MT also increased FSH levels in prepubertal rats of 16 days of age, but no change occurred in 30-day-old and in adult rats. The administration of estrogen-progesterone (EP) to prepubertal rats of 16 days of age induced a significant decrease in serum LH levels as well as in the serotonin (5-HT) and 5-hydroxyindole-acetic acid (5-HIAA) concentrations in the anterior-preoptic hypothalamic area (AH-POA), but not in the medial basal hypothalamus. No modifications in the catecholamine content of these hypothalamic areas were observed in this age group after EP administration. On the contrary, in 30-day-old rats, EP induced a significant LH release as well as an increase in AH-POA concentrations of 5-HT, 5-HIAA and catecholamines.(ABSTRACT TRUNCATED AT 250 WORDS)
Moguilevsky
J A
JA
Departamento de Fisiologia, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Arias
P
P
Szwarcfarb
B
B
Carbone
S
S
Rondina
D
D
D000375:Aging; D000818:Animals; D002395:Catecholamines / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism*; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D007986:Luteinizing Hormone / Q000378:metabolism*; D008781:Methyltyrosines / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism; D012741:Sexual Maturation / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors; D019805:alpha-Methyltyrosine
D002395:Catecholamines; D008781:Methyltyrosines; D018377:Neurotransmitter Agents; D012701:Serotonin; D011374:Progesterone; D004958:Estradiol; D006897:Hydroxyindoleacetic Acid; D019805:alpha-Methyltyrosine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D009638:Norepinephrine